LAE 106
Alternative Names: LAE-106Latest Information Update: 10 Oct 2022
At a glance
- Originator Laekna Therapeutics
- Class Antifibrotics; Hepatoprotectants
- Mechanism of Action Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Hepatic fibrosis
Highest Development Phases
- Research Hepatic fibrosis
Most Recent Events
- 14 Sep 2022 LAE 106 is available for licensing as of 14 Sep 2022. https://www.laekna.com/ (Laekna Therapeutics website, September 2022)
- 14 Sep 2022 Early research in Hepatic fibrosis in China (unspecified route) prior to September 2022 (Laekna Therapeutics pipeline, September 2022)